BES_Mark.jpg
BLUE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Bluebird bio Inc. and Encourages Investors to Contact the Firm
March 28, 2024 21:00 ET | Bragar Eagel & Squire
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against...
RGRD Logo BusinessWire.jpg
BLUE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead the bluebird bio Class Action Lawsuit
March 28, 2024 17:55 ET | Robbins Geller Rudman & Dowd LLP
SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the bluebird bio class action lawsuit seeks to represent purchasers or acquirers of bluebird bio,...
Global Cell Lysis Market
Global Cell Lysis Market Experiences Robust Growth, Expected to Achieve a CAGR of 6.79% Through 2028
March 28, 2024 17:53 ET | Research and Markets
Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Global Cell Lysis Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's...
22157.jpg
Europe 3D Cell Culture Market to Witness Robust Growth Driven by Technological Advancements and Surging Demand in Pharmaceutical Research
March 28, 2024 17:52 ET | Research and Markets
Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Europe 3D Cell Culture Market, Competition, Forecast & Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's offering. ...
fortressbio1.jpg
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
March 28, 2024 16:05 ET | Fortress Biotech, Inc.
Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application...
Logo_EnlivenTherapeutics.png
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
March 28, 2024 16:05 ET | Enliven Therapeutics, Inc.
BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and...
SELLAS Logo.png
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
March 28, 2024 16:05 ET | SELLAS Life Sciences Group, Inc.
Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified...
Unknown.png
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
March 28, 2024 16:05 ET | TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
TelesisBio_Logo_RGB.png
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
March 28, 2024 16:05 ET | Telesis Bio
SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced,...
Candel_Logo_FullColor (4).png
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
March 28, 2024 16:05 ET | Candel Therapeutics
The first cohort of patients were treated with multiple injections of CAN-3110 in the ongoing phase 1b clinical trial.The serial procedures were well tolerated without observed dose-limiting...